CAMBRIDGE, Mass., Nov. 2, 2016 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the
company will host its Third Quarter 2016 investor conference call
and webcast at 4:30 p.m., Eastern time, on Wednesday,
November 9.
The call will cover an update on Merrimack's recent progress as
well as a summary of third quarter 2016 financial results. A press
release detailing the information to be discussed on the call will
be issued the afternoon of Wednesday,
November 9. Investors and the general public are invited to
listen to the call by dialing (877) 564-1301 (domestic) or (224)
357-2394 (international) five minutes prior to the start of the
call and providing the passcode 89606889.
A listen-only webcast of the call will be available in the
Investors section of Merrimack's website, investors.merrimack.com,
and a replay of the call will be archived there for six weeks.
About Merrimack
Merrimack is a fully integrated biopharmaceutical company that
views cancer as a complex engineering challenge. Through systems
biology, which brings together the fields of biology, computing and
engineering, Merrimack aims to decrease uncertainty in drug
development and clinical validation, and move discovery efforts
beyond trial and error. Such an approach has the potential to make
individualized treatment of patients a reality. Merrimack's first
commercial product, ONIVYDE® (irinotecan liposome injection), was
approved by the U.S. FDA in October 2015.With four additional
candidates in clinical studies, several in preclinical development
and multiple biomarkers designed to support patient selection,
Merrimack is building one of the most robust oncology pipelines in
the industry. For more information, please visit Merrimack's
website at www.merrimack.com or connect on Twitter at
@MerrimackPharma.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Merrimack constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Merrimack anticipates that subsequent events and developments will
cause its views to change. However, while Merrimack may elect to
update these forward-looking statements at some point in the
future, Merrimack specifically disclaims any obligation to do
so.
CONTACT:
Geoffrey M. Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/merrimack-announces-timing-of-third-quarter-2016-investor-conference-call-300356167.html
SOURCE Merrimack Pharmaceuticals, Inc.